Genmab — April 2023
-
Godmorgen
-
I don't the full abstract was posted yet: Tisotumab vedotin (TV) in squamous cell carcinoma of head and neck (SCCHN): interim analysis from innovaTV 207 https://aacrjournals.org/cancerres/article/83/8_Supplement/CT164/725551
-
Still not sc. As far as I can see. Study started last year. https://clinicaltrials.gov/ct2/show/NCT05405166
-
no; they have it in their Expected submission timeline in '2025 and beyond' https://www.sanofi.com/dam/jcr:a47dcb49-3067-44bc-9cd1-dc1fd0094b66/2023_04_27_Sanofi_Q1_2023_Results_Presentation.pdf
-
Vi nærmer os sommer od sol - men Genmab aktien må jo nok leve i voldgiftens skygge en rum tid endnu. Er der nogen, der har kendskab til varigheden af behandling af en anke?
-
The Party seeking review must submit its opening brief and any reply brief within [] and [] calendar days, respectively, following the date of the award under review, whereas the opposing Party must submit its responsive brief within [] calendar days of that date. Oral argument shall take place within [] calendar months after the date of the award under review, and the Appeal Arbitrator shall render a decision within [***] calendar days following oral argument.
-
Tak @gentogen . Jeg tror nærmere ca. 9 mdr. Men håber, du har ret
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind